"Profile HIT" (Holistic Individualized Treatment)) (HIT-PRF)

A Prospective Clinical Trial Evaluating the "Profile HIT" (Holistic Individualized Treatment)

The "Holistic Individualized Treatment" (HIT) approach is used to identify treatment priorities, focus areas, and appropriate products for soft tissue filler treatments.

The "Profile HIT" considers the balance between the midface, nose, lips, and chin to improve a patient's appearance. This trial will assess the effectiveness of the Profile HIT algorithm in treating patients with different profile issues (e.g. nasal deformities, volume loss, chin retrusion).

Study Overview

• Status: Recruiting
• Conditions: Aesthetic
• Intervention / Treatment: Drug: Restylane line of injectable

• Study Type: Interventional
• Enrollment (Anticipated): 18
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Kaitlyn Enright; Phone Number: 256 514-488-0163; Email: kenright@vicpark.com

Study Locations

• Canada
  • Quebec
    • Montreal, Quebec, Canada, H3R 3A1
      • Recruiting
      • Erevna Innovations Inc
      • Contact: Andreas Nikolis, MD; Phone Number: 514-488-0163; Email: research@vicpark.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Subjects must voluntarily sign and date an informed consent, including the photography addendum allowing unrestricted use of photographs for the benefit of marketing and educational purposes, approved by an independent ethics committee, before the initiation of any screening or study-specific procedures.
• Subjects must be adult male or female, at least 18 years old.
• Subjects must be willing and able to comply with procedures required in the protocol.
• Subjects must be in good health as per the investigator's judgment based on medical history
• Female subjects that are not pregnant or breastfeeding and are not considering becoming pregnant or donating eggs during the study or for approximately 30 days after the last dose of the study medical device or until the end of the study, whichever is longer.

Exclusion Criteria:

• Subject with uncontrolled systemic disease.

• Subject with or have a history of any medical condition that may place the subject at increased risk following exposure to hyaluronic acid or interfere with the study evaluation, including:

  • Diagnosed myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis, or any other significant disease that might interfere with neuromuscular function
  • History of facial nerve palsy
  • Infection or dermatological condition at the treatment injection sites
  • Marked facial dermatochalasis, deep dermal scarring, excessively thick sebaceous skin, or overly photodamaged skin
• Subject with a history of clinically significant medical conditions or any other reason that the investigator determines would interfere with the subject's participation in this study or would make the subject an unsuitable candidate to receive the study medical intervention
• Subjects with a history of an allergic reaction or significant sensitivity to constituents of the study medical intervention (or its excipients).
• Subjects with porphyria
• Subjects with active diseases, such as inflammation, infection or tumours, in or near the intended treatment sites,
• Subjects with bleeding disorders or taking thrombolytics or anticoagulants.
• Subjects who need to take immunosuppressants.
• Subjects with tattoos, jewelry, or clothing which obscure the treatment area and cannot be removed.
• Subjects who have anticipated the need for surgery or overnight hospitalization during the study.
• Subjects with a history of surgical procedures in the face, including any lifting method (e.g., facial lift, suture lift, thread lift, brow lift, eyelid and eyebrow surgery).
• Subjects with a history of facial treatment with semi-permanent or permanent soft tissue fillers (e.g., poly-L-lactic acid, polyalkylimide, polymethylmethacrylate, polytetrafluoroethylene, and silicone), synthetic implantation and/or autologous fat transplantation.
• Subjects with known active COVID infection within 14 days of baseline treatment.
• Subjects that have been treated with any investigational product within 30 days before the first dose of the study medical device or are currently enrolled in another clinical study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Treatment	Drug: Restylane line of injectable; Restylane fillers are manufactured by Q-Med AB, part of the Galderma Group.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Primary Endpoint - Global Aesthetics Improvement Scale (GAIS)	Frequency of subjects having at least "improved" (e.g., "improved", "much improved" or "very much improved") on the Global Aesthetics Improvement Scale (GAIS), as graded by a blinded evaluator.	At week 8

Collaborators and Investigators

• Sponsor: Erevna Innovations Inc.

Study record dates

Study Major Dates

• Study Start (Actual): March 9, 2023
• Primary Completion (Anticipated): October 31, 2023
• Study Completion (Anticipated): March 9, 2025

Study Registration Dates

• First Submitted: April 6, 2023
• First Submitted That Met QC Criteria: April 6, 2023
• First Posted (Actual): April 19, 2023

Study Record Updates

• Last Update Posted (Actual): May 19, 2023
• Last Update Submitted That Met QC Criteria: May 17, 2023
• Last Verified: May 1, 2023

More Information

Terms related to this study

• Keywords: Hyaluronic acid; Facial Profile; Fillers; Volumization; Patient Assessment
• Other Study ID Numbers: 02-2023-HIT-PRF

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No